David E. I. Pyott
David E. I. Pyott was Chief Executive Officer of Allergan during the period when Botox Cosmetic gained its U.S. glabellar-line approval and the Botox franchise became a major global pharmaceutical and aesthetics business.
In the Botulinum Index graph, Pyott is a commercial-expansion node. He does not explain the scientific origin of botulinum toxin or the first therapeutic development of Oculinum. He explains how Allergan turned Botox from a specialized therapeutic product family into one of the central reference brands in medical aesthetics and neuromodulator market history.
Role Context
Section titled “Role Context”| Field | Detail |
|---|---|
| Historical organization | Allergan, Inc. |
| Historical role | Chief Executive Officer |
| Relevant period | 1998 to the 2015 Actavis acquisition period |
| Graph role | Botox franchise commercialization and Allergan market-strategy node |
| Relevant company node | AbbVie / Allergan |
| Relevant brand node | Botox / Botox Cosmetic |
| Regulatory anchor | FDA approval of Botox Cosmetic for glabellar lines on April 12, 2002 |
Career Notes
Section titled “Career Notes”- Pyott became Allergan’s Chief Executive Officer in 1998, after the company had already acquired Oculinum and renamed the product Botox.
- During his tenure, Allergan pursued the research and commercial pathway that led to Botox Cosmetic’s 2002 U.S. glabellar-line approval.
- Reporting in 2014 described Botox sales as growing from a few hundred million dollars in 2001 to nearly two billion dollars by 2013.
- Actavis agreed to acquire Allergan in 2014, and the transaction closed in 2015, ending Pyott’s role as the legacy Allergan CEO.
Why David Pyott Matters
Section titled “Why David Pyott Matters”Pyott matters because the Botox market story has a distinct commercial phase. Alan B. Scott explains Oculinum and therapeutic development. Jean Carruthers and Alastair Carruthers explain the glabellar-line cosmetic-use pathway. Pyott explains Allergan’s executive period of brand expansion, evidence-building, and market growth.
That role is important to the industry graph because Botox became more than one approved medicine. It became the public reference point for an entire category, shaping how consumers, clinicians, investors, journalists, and competing companies talked about botulinum toxin products.
The commercial story should not be read as a clinical ranking. Botox’s visibility under Allergan does not make its units interchangeable with other products or establish that Botox is universally safer, stronger, longer-lasting, or more appropriate than another labeled toxin product.
Allergan and Botox Cosmetic Context
Section titled “Allergan and Botox Cosmetic Context”The 2002 FDA approval of Botox Cosmetic for glabellar lines is the clearest regulatory turning point in Pyott’s Botox-specific story. The approval created a distinct aesthetic label context for a product family that already had therapeutic history.
Allergan’s later Botox growth also depended on therapeutic indication expansion, professional adoption, direct category education, and the wider rise of medical aesthetics. Pyott’s page is therefore a company-strategy anchor rather than a product-origin page.
Activity and Public Context
Section titled “Activity and Public Context”Pyott is most useful when readers are following the transition from Botox as a specialized medical product to Botox as the best-known neuromodulator brand. His page should link to Allergan / AbbVie history, Botox label context, and the people who explain earlier scientific and clinical origin stages.
For current ownership, readers should use AbbVie / Allergan. For current product interpretation, readers should use Botox and the current prescribing information.